Protein C anticoagulant system in patients with interstitial lung disease.

Content Provider	Semantic Scholar
Author	Kobayashi, Honami Gabazza, Esteban C. Taguchi, Osamu Wada, Hideo Takeya, Hiroyuki Nishioka, Junko Yasui, Hiroki Kobayashi, Tsutomu Hataji, Osamu Suzuki, Koji A. O. Adachi, Yukihiko
Copyright Year	1998
Abstract	Excessive procoagulant activity in the alveolar space may play a relevant role in the pathogenesis of pulmonary fibrosis. Hypercoagulability results from the disruption of the balance between the procoagulant and anticoagulant factors. The aim of this study was to assess the levels of molecular markers of the anticoagulant protein C (PC) pathway in the bronchoalveolar lavage fluid (BALF) and plasma of 11 patients with idiopathic pulmonary fibrosis (IPF), 14 with sarcoidosis and 16 with collagen vascular disease (CVD)-associated interstitial lung disease (CVD-ILD). Six healthy nonsmoking volunteers served as control subjects. BALF concentrations of the marker of clotting activation, thrombin- antithrombin III complex (TAT), in patients with sarcoidosis and CVD-ILD were significantly greater than those in control subjects. PC levels in BALF were markedly higher in patients with IPF (610 +/- 150 ng/ml), sarcoidosis (680 +/- 170 ng/ml), and CVD-ILD (1,580 +/- 600 ng/ml) than in control subjects (230 +/- 140 ng/ml). BALF concentrations of activated PC-PC inhibitor (APC-PCI) complex were significantly decreased in IPF (0.46 +/- 0.16 ng/ml), sarcoidosis (0. 43 +/- 0.11 ng/ml), and CVD-ILD (0.50 +/- 0.15 ng/ml) patients as compared with control subjects (1.08 +/- 0.23 ng/ml). APC-PCI/PC ratios were significantly lower in patients with IPF (2.70 +/- 1.74 ng/microg), sarcoidosis (1.94 +/- 0.82 ng/microg), and CVD-ILD (1.89 +/- 0.68 ng/microg) than in control subjects (15.91 +/- 8.45 ng/microg). Plasma levels of APC- PCI and the APC-PCI/PC ratio were also significantly decreased in patients with CVD-ILD as compared with control subjects. Overall, these findings suggest that decreased PC activation with increased procoagulant activity occurs in patients with ILD.
Starting Page	1
Ending Page	6
Page Count	6
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://ajrccm.atsjournals.org/content/157/6/1850.full.pdf
PubMed reference number	9620917v1
Volume Number	157
Issue Number	6
Part	1
Journal	American journal of respiratory and critical care medicine
Language	English
Access Restriction	Open
Subject Keyword	Anticoagulants Biological Markers Bronchoalveolar Lavage Fluid Cardiovascular Diseases Collagen Diseases Idiopathic Pulmonary Fibrosis Irrigation Lung Diseases, Interstitial Lung diseases Microgram per Liter Patients Protein C Thrombophilia Vascular Diseases
Content Type	Text
Resource Type	Article